TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12240782

Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in orange juice (180 mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in tomato juice (180 mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in strained pears (1 tablespoon)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intact lansoprazole capsule with water (180 mL)
Number of subjects: 20
Study: 10707109

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) with diethylcarbamazine (DEC; 6 mg/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) with albendazole (400 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) with albendazole (400 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 51
Study: 8945794

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk-screening and intervention (one-year program)
Number of subjects: 2984

Group type: COMPARATOR
Intervention: Control group (not offered intervention)
Number of subjects: 2984
Study: 2248082

Group type: COMPARATOR
Intervention: Moclobemide 100 mg single dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moclobemide 200 mg single dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moclobemide 300 mg single dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg 3 times daily for 1 week
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 100 mg 3 times daily for 1 week
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg 3 times daily for 1 week
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg 3 times daily for 1 week (24 hours after last dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 100 mg 3 times daily in depressed patients
Number of subjects: 17
Study: 6446929

Group type: EXPERIMENTAL
Intervention: 2‐methyl histamine (H1‐receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1‐receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4‐methyl histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimaprit (H2‐receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2‐methyl histamine and either 4‐methyl histamine or dimaprit
Number of subjects: 0
Study: 30655038

Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 2 hours after thrombolysis (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 2-12 hours after thrombolysis (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 12-24 hours after thrombolysis (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 0
Study: 28701162

Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 11
Study: 25648155

Group type: EXPERIMENTAL
Intervention: Intensified HH interventions (S2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard-of-care HH education every 3 months (S1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensified HH interventions (S2) for HCWs with lower stages of HH commitment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3) for HCWs with lower stages of HH commitment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3) for HCWs with higher stages of HH commitment
Number of subjects: 125
Study: 23963616

Group type: EXPERIMENTAL
Intervention: Kinesiologic tape
Number of subjects: 40

Group type: COMPARATOR
Intervention: No kinesiologic tape (control)
Number of subjects: 40
Study: 22802250

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (120 mg twice daily for 15 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Raltegravir alone (400 mg)
Number of subjects: 18
Study: 19239460

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dutasteride and tamsulosin
Number of subjects: 0
Study: 17601495

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 444
Study: 15351864

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous unfractionated heparin (continuous infusion of 100 IU/kg/daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Normal saline solution (50 ml/daily as a continuous infusion)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous unfractionated heparin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 128
Study: 11527171

Group type: EXPERIMENTAL
Intervention: Capitonnage (n = 23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open method (n = 19)
Number of subjects: 42
Study: 9727959

Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (MCPP), 0.35 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: meta-chlorophenylpiperazine (MCPP)
Number of subjects: 0
Study: 7984968

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (retreatment once or twice)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment
Number of subjects: 9
Study: 2531910

Group type: EXPERIMENTAL
Intervention: mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty‐five days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: dexamethasone (24 mg/die i.v. for the first ten days)
Number of subjects: 57
Study: 392744

Group type: EXPERIMENTAL
Intervention: Acetard (controlled-release acetylsalicylic acid), 1 g X 4 or 2 g X 2 per day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Magnecyl (instant-release acetylsalicylic acid), 1 g X 4 daily
Number of subjects: 24
Study: 31519441

Group type: EXPERIMENTAL
Intervention: eCPAP
Number of subjects: 44

Group type: COMPARATOR
Intervention: dCPAP
Number of subjects: 44
Study: 30318492

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg per day
Number of subjects: 1077
Study: 28241419

Group type: EXPERIMENTAL
Intervention: Iodine fortified milk
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no iodine fortified milk)
Number of subjects: 84
Study: 26232570

Group type: EXPERIMENTAL
Intervention: Self-management training program (4 training sessions on the nature of epilepsy and self-management)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 23683841

Group type: EXPERIMENTAL
Intervention: Combined group CBT (eight, 2‐hour weekly sessions) plus individual dilemma‐focused therapy (eight, 1‐hour weekly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT alone (eight, 2‐hour group weekly sessions plus eight, 1‐hour individual weekly sessions)
Number of subjects: 0
Study: 21819539

Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU kg(‐1) per 24 h) for acute venous thromboembolism
Number of subjects: 87
Study: 18321497

Group type: EXPERIMENTAL
Intervention: Serum FSH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum INHB
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum AMH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Volume of the larger testis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of INHB and AMH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of FSH, AMH, INHB, or volume of the larger testis
Number of subjects: 51
Study: 17298853

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m² plus gemcitabine 1000 mg/m² i.v. on days 1 and 8 with intra-patient alternated dose escalation up to 100 and 1200 mg/m², respectively, over three cycles (arm A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m² followed by gemcitabine 1000 mg/m² i.v. (100 min) on days 1 and 8 (arm B)
Number of subjects: 98
Study: 16544440

Group type: EXPERIMENTAL
Intervention: Pegaptanib, injected into the eye every six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14559745

Group type: EXPERIMENTAL
Intervention: Stratified design in Mwanza trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified design in Masaka trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified design in Rakai trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual matching of communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmatched study designs with smaller communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Mwanza trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Masaka trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Rakai trial
Number of subjects: 0
Study: 11915854

Group type: EXPERIMENTAL
Intervention: Alora 0.1 mg/day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Alora 0.05 mg/day
Number of subjects: 321

Group type: COMPARATOR
Intervention: CEE 0.625 mg/day
Number of subjects: 321

Group type: COMPARATOR
Intervention: CEE 1.25 mg/day
Number of subjects: 321
Study: 7718674

Group type: EXPERIMENTAL
Intervention: Clomipramine (12.5 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers and alcoholics (control group)
Number of subjects: 0
Study: 2167788

Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 1 mumol/l
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 2 mumol/l
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 4 mumol/l
Number of subjects: 4

Group type: COMPARATOR
Intervention: Aspirin infusion at 0 mumol/l (control)
Number of subjects: 4
Study: 7232461

Group type: EXPERIMENTAL
Intervention: Ethanol (1-6 oz of 95-proof)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secobarbital (30-300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25-100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30676323

Group type: EXPERIMENTAL
Intervention: Real Kinesio Taping (KT) application
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham Kinesio Taping (KT) application
Number of subjects: 40
Study: 27563177

Group type: EXPERIMENTAL
Intervention: WaveOne (Group WO)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: ProTaper Universal (Group PU)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Mtwo (Group Mt)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (nonvital teeth)
Number of subjects: 152
Study: 24979315

Group type: EXPERIMENTAL
Intervention: Primary Care Stepping Stones Triple P (intervention group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 64
Study: 22736123

Group type: EXPERIMENTAL
Intervention: Individualized fluid therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional fluid therapy
Number of subjects: 60
Study: 20138272

Group type: EXPERIMENTAL
Intervention: Vapor-phase nitrogen storage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Liquid nitrogen storage
Number of subjects: 90
Study: 18525035

Group type: EXPERIMENTAL
Intervention: Extended nevirapine
Number of subjects: 3016

Group type: EXPERIMENTAL
Intervention: Extended dual prophylaxis (nevirapine plus zidovudine)
Number of subjects: 3016

Group type: COMPARATOR
Intervention: Control regimen (single‐dose nevirapine plus 1 week of zidovudine)
Number of subjects: 3016
Study: 15715193

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600mg/d) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1000 microg/d) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600mg/d) and Fluticasone propionate (1000 microg/d) for 10 weeks
Number of subjects: 0
Study: 12079630

Group type: EXPERIMENTAL
Intervention: 1.45 microm diode laser treatment with an average power of 12 W, heating times from 150 ms to 500 ms, applied over two to six treatment cycles.
Number of subjects: 10
Study: 10623054

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 98000

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 98000
Study: 7564350

Group type: EXPERIMENTAL
Intervention: 20 mg quinapril plus 12.5 mg hydrochlorothiazide (HCTZ)
Number of subjects: 291

Group type: COMPARATOR
Intervention: 20 mg quinapril monotherapy
Number of subjects: 291

Group type: COMPARATOR
Intervention: 12.5 mg hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Combination therapy (quinapril + HCTZ)
Number of subjects: 291
Study: 2209135

Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus triamterene 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus spironolactone 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bendrofluazide plus triamterene 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose triamterene
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study: 7188585

Group type: EXPERIMENTAL
Intervention: Prizidilol (400-800 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prizidilol (mean: 447 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prizidilol (mean: 700 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prizidilol
Number of subjects: 24
Study: 30618355

Group type: EXPERIMENTAL
Intervention: Repeated words in discourse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word identification task
Number of subjects: 0
Study: 31117809

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) sinus implant (1350 mcg) and MF nasal spray (MFNS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: MF nasal spray (MFNS) alone
Number of subjects: 400
Study: 29072002

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of 'Yaotong'-point and local Ashi-points for 20 min, combined with lumbar movement, 3 times a week for 1 week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group treated with oral loxoprofen sodium tablets (60 mg, twice a day, for one week)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups showed significant decrease in ROM and VAS scores post-treatment (P<0.01)
Number of subjects: 46
Study: 24785978

Group type: EXPERIMENTAL
Intervention: Statins (medium potency)
Number of subjects: 656
Study: 23941282

Group type: EXPERIMENTAL
Intervention: Modified balloon dilatation treatment and regular dysphagia therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular dysphagia therapy only
Number of subjects: 30
Study: 21217456

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 351

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 351
Study: 19835591

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) applied with a sponge (40 units each nostril)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alternative medication (BTA or saline) for non-responders in subgroups C and D
Number of subjects: 20
Study: 16639069

Group type: EXPERIMENTAL
Intervention: Oral enteral nutrition supplement plus supplemental parenteral nutrition (PN+)
Number of subjects: 152
Study: 14964681

Group type: EXPERIMENTAL
Intervention: Optibond Solo (OS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (SB1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SB1+Revolution (R)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop (PLP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (SB1) with flowable composite layer
Number of subjects: 25
Study: 10960403

Group type: EXPERIMENTAL
Intervention: 35 degrees C treated tube group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 45 degrees C treated tube group
Number of subjects: 150

Group type: COMPARATOR
Intervention: untreated tube group
Number of subjects: 150
Study: 9026581

Group type: EXPERIMENTAL
Intervention: Uric acid in aqueous humor of patients with cataract
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison between cataract patients and control group
Number of subjects: 32
Study: 1538348

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 83
Study: 6239300

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Haloperidol (0.014 mg/kg IM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Propranolol (0.1 mg/kg IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Thymoxamine (0.1 mg/kg IV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dextroamphetamine (0.3 mg/kg IV) with Placebo
Number of subjects: 12
Study: 31065996

Group type: EXPERIMENTAL
Intervention: Prior exposure to second- and third-generation cephalosporins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior exposure to fluoroquinolones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged hospitalisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being elderly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Having genitourinary disease
Number of subjects: 0
Study: 27206564

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS)
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia morphine (IV PCA morphine)
Number of subjects: 1882
Study: 26348166

Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 746

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 746
Study: 23026438

Group type: EXPERIMENTAL
Intervention: Umeclidinium 125 μg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Umeclidinium 250 μg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Umeclidinium 500 μg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Umeclidinium
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 20740685

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 19830352

Group type: EXPERIMENTAL
Intervention: Single phototherapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Double phototherapy
Number of subjects: 77
Study: 16887429

Group type: EXPERIMENTAL
Intervention: Neridronate treatment (2 mg/kg administered intravenously for 2 consecutive days, every 3 months)
Number of subjects: 10
Study: 14962524

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (16 mmol over 15 min and then 65 mmol over 24 h)
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2589

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2589
Study: 11298538

Group type: EXPERIMENTAL
Intervention: 0.2% SDZ ASM 981 cream
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 0.6% SDZ ASM 981 cream
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 1.0% SDZ ASM 981 cream
Number of subjects: 260

Group type: COMPARATOR
Intervention: 0.1% betamethasone-17-valerate cream (BMV)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 260
Study: 9613279

Group type: EXPERIMENTAL
Intervention: Whoosh test (injection of air into the caudal epidural space)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clinical impression alone
Number of subjects: 131
Study: 7924125

Group type: EXPERIMENTAL
Intervention: 20 mg/day cetirizine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60 mg/day cetirizine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2539937

Group type: EXPERIMENTAL
Intervention: Standard 3100 kJ cold meal
Number of subjects: 12
Study: 1100055

Group type: EXPERIMENTAL
Intervention: Catalase (Optidase) injections
Number of subjects: 648

Group type: COMPARATOR
Intervention: Standard treatment without catalase
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Catalase (Optidase) injections in extended study
Number of subjects: 648
Study: 31782562

Group type: EXPERIMENTAL
Intervention: Selenium yeast (SY)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Sodium selenite (SS)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Se-Unsupplemented control diet
Number of subjects: 360
Study: 31099442

Group type: EXPERIMENTAL
Intervention: Proposed free-running T1 mapping method
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saturation recovery single-shot acquisition (SASHA) sequence
Number of subjects: 9

Group type: COMPARATOR
Intervention: Modified Look-Locker inversion recovery (MOLLI) sequence
Number of subjects: 9

Group type: COMPARATOR
Intervention: MOLLI sequence
Number of subjects: 9

Group type: COMPARATOR
Intervention: SASHA sequence
Number of subjects: 9
Study: 28619771

Group type: EXPERIMENTAL
Intervention: Revealed CPR evaluation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concealed CPR evaluation
Number of subjects: 0
Study: 25814638

Group type: COMPARATOR
Intervention: iDISK technique
Number of subjects: 36
Study: 23435795

Group type: EXPERIMENTAL
Intervention: Intensive intervention of 15 dietitian visits providing lifestyle advice
Number of subjects: 171

Group type: COMPARATOR
Intervention: Light (control) intervention of four visits
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Light (control) intervention
Number of subjects: 171
Study: 21463967

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29